For three years, one lupus patient managed her condition the way most do: a rotation of immunosuppressants, corticosteroids, and the antimalarial drug hydroxychloroquine that she took every morning like clockwork. Joint pain never fully went away. Fatigue was a constant companion. Then she enrolled in a clinical trial testing something entirely different.
Doctors extracted her T cells, genetically reprogrammed them to recognize and destroy the B cells driving her disease, and infused them back into her body. Eighteen months later, she remains in remission. No daily pills. No round of steroids when flares threatened. "It felt like my immune system had been reset," she told researchers.
Her experience is becoming less exceptional by the month. The treatment she received, called CAR T cell therapy, was originally developed to fight blood cancers. It has now emerged as one of the most promising avenues for treating autoimmune disease in decades. And the implications extend far beyond lupus.
What CAR T Cell Therapy Actually Does
To understand why this approach is generating so much excitement, it helps to know what CAR T cells are and how they work. T cells are a type of white blood cell that roams your body looking for threats. Normally they identify invaders by reading the molecular markers, called antigens, displayed on other cells. The problem with autoimmune diseases is that your immune system has already turned against your own tissue, mistaking healthy cells for threats.
CAR T cell therapy sidesteps this by giving T cells a targeting upgrade. Scientists harvest T cells from the patient, genetically engineer them to express a chimeric antigen receptor, or CAR, on their surface, then expand millions of copies in the lab before infusing them back. When those engineered cells encounter their target antigen, they bind to it, activate, multiply, and destroy whatever cell is carrying it.
In cancer treatment, the target is typically CD19, a protein found on the surface of B cells. Many blood cancers arise from B cells going rogue, so eliminating them can send the disease into remission. CD19 is also a meaningful target for many autoimmune diseases, because B cells play a central role in driving immune misfires. They produce the antibodies that attack healthy tissue, and they release signaling molecules that amplify inflammation throughout the body.
The first two CAR T therapies received FDA approval in 2017: tisagenlecleucel, marketed as Kymriah, for B-cell precursor acute lymphoblastic leukemia, and axicabtagene ciloleucel, sold as Yescarta, for diffuse large B-cell lymphoma. By 2022, six CAR T therapies had gained regulatory approval in the United States [1].
The Autoimmune Repurposing
The leap from cancer to autoimmune disease was conceptually straightforward, even if the clinical path was not. If CAR T cells could eliminate cancerous B cells, the thinking went, they might also eliminate the overactive B cells driving conditions like lupus, multiple sclerosis, and rheumatoid arthritis.
Early clinical results have been striking. Patients with systemic lupus erythematosus who failed conventional therapies have achieved sustained remission after a single CAR T infusion. Similar signals have emerged in trials targeting MS, ulcerative colitis, and systemic sclerosis. The mechanism is the same in each case: eliminate the B cells, interrupt the autoimmune cascade, and give the immune system a chance to reset rather than continue suppressing symptoms indefinitely.
This represents a fundamental shift in how doctors might approach autoimmune disease. Current treatments for conditions like lupus rely heavily on broad immunosuppression, which dampens the entire immune system and leaves patients vulnerable to infections. CAR T therapy is targeted. It eliminates a specific cell population, and over time, new B cells regenerate from stem cells in the bone marrow, typically without restoring the autoimmune programming that caused the original problem.
The concept of using CAR T cells to reset the immune system has also opened a research path involving regulatory T cells, or Tregs. These are the immune system's peacekeepers, responsible for maintaining peripheral tolerance and preventing the body from attacking itself. Researchers are investigating whether Tregs outfitted with CARs could confer antigen-specific tolerance, essentially teaching the immune system to stop attacking a particular target without broadly suppressing defenses [5]. The 2025 Nobel Prize in Physiology or Medicine recognized discoveries in immune regulation, lending further scientific weight to this area of investigation.
The Scale of the Problem
The urgency behind this research is driven by the sheer prevalence of autoimmune disease. An estimated 10 percent of the population in the United Kingdom is affected by one of more than 80 distinct autoimmune conditions identified so far [4]. Rates are significantly higher in women than men, often by a ratio of two to one or more.
Lupus illustrates the human and economic burden clearly. The disease affects between 20 and 70 per 100,000 people depending on the country, striking women of childbearing age about nine times more frequently than men [2]. There is no cure. The 15-year survival rate is approximately 80 percent, and cardiovascular disease remains the most common cause of death, driven partly by the chronic inflammation that characterizes the condition [2].
Multiple sclerosis affects approximately 2.8 million people globally, with women outnumbering men by nearly three to one and symptom onset typically occurring around age 30 [3]. Like lupus, it cannot be cured. Disease-modifying therapies can reduce relapse rates and slow progression, but they require ongoing use and come with their own risk profiles.
The cumulative burden of these conditions, in quality of life, lost productivity, and healthcare expenditure, is enormous. A treatment that could meaningfully alter the course of any one of them, let alone multiple conditions through a shared mechanism, represents a prize of considerable magnitude.
What Remains Unknown
Important questions persist about durability, safety, and accessibility. The data so far covers a relatively short timeframe. Most autoimmune trials have followed patients for months to a couple of years post-infusion. Whether the reset holds for decades remains an open question. In cancer treatment, some patients have maintained remission for years, but the dynamics of autoimmune disease differ in ways that are not yet fully understood.
Safety is another consideration. CAR T therapy can cause cytokine release syndrome, an inflammatory response that ranges from mild flu-like symptoms to severe, life-threatening complications. Neurotoxicity has also been observed in some cancer patients. The risk-benefit calculation looks different when treating life-threatening blood cancers than it does for chronic autoimmune conditions that, while debilitating, are not immediately fatal.
Cost is perhaps the most immediate practical barrier. CAR T therapies for cancer command price tags well into the hundreds of thousands of dollars per treatment. Manufacturing personalized cell therapies is expensive, and health systems are already straining under the weight of chronic disease management. Scaling this approach to millions of autoimmune patients would require either dramatic cost reductions or a fundamental rethink of how such treatments are funded.
The Road Ahead
None of these questions are dealbreakers. They are the normal friction points that accompany any genuinely novel therapeutic approach moving through clinical development. The evidence base is growing, trials are expanding, and the mechanistic rationale is solid.
What makes CAR T cell therapy for autoimmune disease feel different is the scale of the potential. A treatment that could replace a lifetime of symptom management with a single intervention, targeting the root cause rather than dampening downstream effects, would represent a category shift in how medicine approaches immune dysfunction.
For patients with severe lupus, the wait for answers cannot come fast enough. The disease takes years of life in small daily increments. Clinical trials have given some patients something they had stopped believing was possible: a day without calculating how their joints felt, how much energy they had left, whether the rash on their face meant a flare was building. Whether CAR T therapy generalizes from promising trial results to practical clinical reality will define a significant chapter in medicine's relationship with autoimmune disease.